Kosmidis P A, Iliopoulos E, Pentea S
Second Department of Medical Oncology, Metaxa Cancer Hospital, Piraeus, Greece.
Cancer. 1988 May 1;61(9):1736-40. doi: 10.1002/1097-0142(19880501)61:9<1736::aid-cncr2820610903>3.0.co;2-t.
Malignant thymoma (MT) is a rare tumor that is often associated with myasthenia gravis (MG). This tumor is considered resistant to chemotherapy. We had the opportunity to treat five patients with MT with cyclophosphamide 800 mg/m2, Adriamycin 50 mg/m2, and vincristine 1.4 mg/m2 (CAV) in cycles of 21 days. Two patients with MG that was resistant to antimyasthenic drugs immediately responded to this combination. One patient with only MT had a complete response, and two patients with only MT had a partial response. Two out of the five patients are still alive and free of disease. Two patients died of disease, and one died from a neutropenia-induced respiratory tract infection. It is concluded that this combination chemotherapy is active in MT and MG and deserves additional trials.
恶性胸腺瘤（MT）是一种罕见肿瘤，常与重症肌无力（MG）相关。该肿瘤被认为对化疗耐药。我们有机会用环磷酰胺800mg/m²、阿霉素50mg/m²和长春新碱1.4mg/m²（CAV），以21天为周期治疗5例MT患者。2例对抗肌无力药物耐药的MG患者对该联合治疗立即产生反应。1例仅患有MT的患者完全缓解，2例仅患有MT的患者部分缓解。5例患者中有2例仍存活且无疾病。2例患者死于疾病，1例死于中性粒细胞减少引起的呼吸道感染。结论是这种联合化疗对MT和MG有效，值得进一步试验。
